Comparative Pharmacology
Head-to-head clinical analysis: GENOSYL versus NETROMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENOSYL versus NETROMYCIN.
GENOSYL vs NETROMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Genosyl (sodium phenylbutyrate) is a prodrug that is metabolized to phenylacetate, which conjugates with glutamine via acetylation to form phenylacetylglutamine. This alternative pathway facilitates waste nitrogen excretion in patients with urea cycle disorders.
Netromycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis in bacteria.
5 mg orally once daily for 14 days, then 2.5 mg orally once daily thereafter.
4-6 mg/kg IV once daily for serious infections; 1.5-2 mg/kg IV every 8 hours for gram-negative infections. Administered as intravenous infusion over 30-60 minutes.
None Documented
None Documented
Terminal half-life 3.5 hours; clinically relevant for dosing every 6-8 hours in renal impairment.
Terminal elimination half-life is 2-3 hours in adults with normal renal function, but may extend to 24-48 hours in patients with impaired renal function.
Renal: 85% unchanged; biliary/fecal: 15% as metabolites.
Renal excretion of unchanged drug accounts for 80-90% of elimination via glomerular filtration; biliary/fecal elimination is minimal (<5%).
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic